NCT01351155

Brief Summary

In patients with acute respiratory failure (ARF) undergoing noninvasive ventilation (NIV), the main complication of the use of the mask is the development of decubitus, sometimes so severe and painful as to force a suspension of the NIV itself . The lesions are mainly located at the nasal bridge, as at this level the skin thin and placed directly on the bone is particularly vulnerable to the injury as consequence of the friction and pressure induced by the movement of the mask. The strategy of prevention and treatment commonly adopted is the application of hydrocolloids. However, precise data are lacking about the demonstration of the effectiveness of these devices and the possibility of using other protective devices. The purpose of this study was to evaluate the usefulness of large-scale three different systems of protection vs. no protection in preventing the development of decubitus lesions in patients receiving NIV for an episode of ARF.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
252

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 10, 2011

Completed
7 months until next milestone

Study Start

First participant enrolled

December 1, 2011

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

December 31, 2014

Status Verified

December 1, 2014

Enrollment Period

3.4 years

First QC Date

May 5, 2011

Last Update Submit

December 29, 2014

Conditions

Keywords

acute respiratory failurenoninvasive ventilation

Outcome Measures

Primary Outcomes (1)

  • Failure rate of the prevention of the facial mask ventilation-induced skin damage in the three interventional groups and in the control group

    7 days

Secondary Outcomes (4)

  • Mask-induced discomfort

    7 days

  • Costs for skin protection

    7 days

  • Prediction of NIV-induced skin damage

    7 days

  • Success of NIV

    Up to 30 days

Study Arms (4)

polyurethane foam (Allewyn adesive)

ACTIVE COMPARATOR

Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Device: Skin protective dressing device

polyurethane film (Tegaderm)

ACTIVE COMPARATOR

The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Device: Skin protective dressing device

Hydrocolloid (Duoderm)

ACTIVE COMPARATOR

Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Device: Skin protective dressing device

Control

NO INTERVENTION

In this no-intervention arm, any skin protective dressing devices is applied before NIV starting

Interventions

Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

Hydrocolloid (Duoderm)polyurethane film (Tegaderm)polyurethane foam (Allewyn adesive)

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hypoxemic-hypercapnic acute respiratory failure (while in O2-therapy):
  • pH\<7.30,
  • PaCO2\>50 mmHg,
  • PaO2/FiO2\<250,
  • respiratory rate\>25/min and use of accessory respiratory muscles
  • Pure Hypoxemic acute respiratory failure(while in O2-therapy):
  • pH\>7.35
  • PaCO2\< 50 mmHg
  • PaO2/FiO2\<250
  • respiratory rate\>25/min and use of accessory respiratory muscles
  • For both types of acute respiratory failure: Signed informed consent by the patient or next keen. Age more than 20 year's old

You may not qualify if:

  • cardiac arrest
  • severe hemodynamic instability (\> 1 vasoactive amine for more than 24 hours)
  • acute coronary syndrome (instable angina/AMI)
  • refusal of NIV
  • anatomic abnormalities interfering with mask fitting
  • pre-existent nasal lesions;
  • NIV for\< 24 hours
  • kwon hypersensitivity to hydrocolloid and polyurethane
  • cancel of informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pulmonary Division With Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy

Lucca, 55100, Italy

RECRUITING

Related Publications (1)

  • Weng MH. The effect of protective treatment in reducing pressure ulcers for non-invasive ventilation patients. Intensive Crit Care Nurs. 2008 Oct;24(5):295-9. doi: 10.1016/j.iccn.2007.11.005. Epub 2008 Feb 1.

Study Officials

  • Raffaele Scala, MD, FCCP

    PULMONARY DIVISION WITH RESPIRATORY INTENSIVE CARE UNIT, S. DONATO HOSPITAL, AREZZO, ITALY

    STUDY CHAIR

Central Study Contacts

Raffaele Scala, MD, FCCP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 5, 2011

First Posted

May 10, 2011

Study Start

December 1, 2011

Primary Completion

May 1, 2015

Study Completion

October 1, 2015

Last Updated

December 31, 2014

Record last verified: 2014-12

Locations